Dr. Rubina Qamar
Claim this profileAurora Saint Luke's Medical Center
Studies Parotid Gland Cancer
Studies Lung Cancer
24 reported clinical trials
68 drugs studied
About Rubina Qamar
Education:
- Earned MD from Dow University of Health Sciences.
- Completed Internship at Civil Hospital/Dow Medical College.
- Residency in Internal Medicine at Loyola University Medical Center.
- Fellowship in Hematology/Oncology at Loyola University Medical Center (ACGME accredited).
Experience:
- Board certified in Hematology and Medical Oncology by the American Board of Internal Medicine.
- Affiliated with Aurora St. Luke's Medical Center, Aurora St. Luke's South Shore, and Aurora Sinai Medical Center.
Area of expertise
1Parotid Gland Cancer
Stage IV
Stage III
Stage II
2Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Rubina Qamar is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
More about Rubina Qamar
Clinical Trial Related4 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Rubina Qamar has experience with
- Paclitaxel
- Atezolizumab
- Docetaxel
- Carboplatin
- Pembrolizumab
- Gemcitabine Hydrochloride
Breakdown of trials Rubina Qamar has run
Parotid Gland Cancer
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Rubina Qamar specialize in?
Is Rubina Qamar currently recruiting for clinical trials?
Are there any treatments that Rubina Qamar has studied deeply?
What is the best way to schedule an appointment with Rubina Qamar?
What is the office address of Rubina Qamar?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.